most normal cells yet allows for great savings in terms of time. Tanigawa et al. (1982) , using both cell lines and cells prepared directly from human tumours, reported good correlations between the measured clonogenic survival and the depression in uptake of [3H]TdR in drug-treated cells compared to controls. A liquid top layer system where cells are cultured over an agar base as developed by Friedman & Glaubiger (1982) offers the advantage over the latter technique as cells can be harvested directly and do not have to be released from the supporting gel.
To determine the potential application of a short term labelling assay we have directly compared the soft agar clonogenic assay, developed by Courtenay & Mills (1978) , with the short term test developed by Friedman & Glaubiger (1982) based on the inhibition in uptake of [3H]TdR. We have used human tumour xenograft cells of low cloning efficiency in soft agar as opposed to high cloning established cell lines as these cells approximate more closely to those obtained from tumour biopsy samples.
Details of the xenografts studied are summarised in Table I . Tumour lines were routinely maintained in thymectomised, irradiated CBA mice (Steel et al., 1978) . Single cell suspensions were prepared from the xenografts and finally filtered through a 27,um Time course experiments demonstrated that the four xenograft lines tested showed very individual patterns in the rate of [3H]TdR uptake over the first week in culture. V15 showed a decreasing rate of [3H]TdR uptake. HX99 displayed an initial increase in uptake followed by a plateau phase with the rate of uptake remaining virtually unchanged after the second day in culture. Both V24 and V7 showed an increase in the rate of uptake of label over the first 7 days in culture. Increasing the cell seeding density did not change the overall pattern of [3H]TdR uptake. The V7 xenograft line was used in all subsequent experiments. Dose response data for the V7 xenograft following exposure to radiation and melphalan, cisplatin and vinblastine are shown in Figures 1 and  2 . All data, where a direct comparison of the two assays was possible, are summarised in Figure 3 . The data show good agreement for the agents tested over the first 1.5 to 2 decades of cell response. There is however an apparent increase in resistance as measured by the [3H]TdR uptake assay once the rate of uptake of [3H]TdR falls to 1% and below that of controls. The plateau in response (Figures 1 and 2a) is similar to the findings of Twentyman et al. (1984) who noted the tendency for the [3H]TdR assay to plateau at between one to two decades of cell response after treatment of H69 lung xenograft cells with X-rays and the cytotoxic drugs adriamycin, melphalan, nitrogen mustard and CCNU.
In the case of primary tumour cells and slowgrowing cell lines, 4 days in culture may only represent 1 or 2 cell divisions and assaying at this time point may well pre-empt full recovery from the drug/radiation-perturbed state (Weisenthal, 1981) .
In spite of this our initial results with the low cloning V7 xenograft line indicate that cell response as determined by the [3H]TdR uptake assay following short term culture of 4 to 6 days is in good agreement with clonogenic survival over the first two decades of cell kill. Increasing the time of assay in the [3H]TdR uptake experiments from day 4 to days 5 and 6 had little effect on the overall measured cell response following radiation doses of 1 and 3 Gy. The mean inhibition in [3H]TdR uptake at these doses was 0.26 and 0.026 respectively and the comparative clonogenic survival was 0.22 and 0.015.
Presumably, both proliferative but nonclonogenic and truly-clonogenic cells will either show unperturbed growth, repair of damage followed by subsequent growth or cell death. The combination of these factors plus cycle delay may well give rise to the apparent decreased sensitivity to higher doses of drugs and radiation. A limitation of working with cells of low cloning efficiency is the narrow range of cell kill measurable without increasing the initial number of cells plated. Our clonogenic survival data is therefore limited below the 0.01 level and no comments can be made concerning the clonogenic survival corresponding to the plateau regions seen in the [3H]TdR uptake assay (Figures 1 and 2a) . Current work involving both autoradiography and further investigating the change in response between days 0 and 6 for both high and low cloning lines may explain firstly which cell population(s) are responsible for uptake of label in the first few days of culture and secondly how long it takes doomed cells to die and cease incorporation of labelled thymidine.
We plan to further these studies to investigate [3H]TdR uptake in our other low cloning xenograft lines and in primary samples of human tumours. Provided reasonable levels of label uptake are obtained in primary tumour cells, the 4 day labelling uptake assay may be of use for individual patient chemosensitivity testing. As the [3H]TdR uptake assay does not require the complete disaggregation of cell clumps into a single cell suspension, this assay could well increase the numbers of samples available for drug testing, shorten the time required for results and increase the potential for an effective individualised patient chemotherapy. 
